2022_Outcomes_Digi | Page 42

• Minimally invasive surgical aortic valve repair / replacement
• TAVR for patients with severe aortic stenosis
• Transcatheter aortic valve-in-valve replacement for degenerated aortic valve bioprosthesis in patients with aortic stenosis or aortic insufficiency
• Transcatheter mitral valve repair ( TMVR ) therapy for patients at high risk for surgical intervention
• Transcatheter mitral valve-in-valve replacement for degenerated mitral prosthesis in patients with mitral regurgitation or mitral stenosis
• Balloon mitral valvuloplasty for patients with mitral stenosis
• Percutaneous tricuspid valve repair
• Left atrial appendage closure via percutaneous and minimally invasive approaches
• Percutaneous patent foramen ovale closure
• Percutaneous atrial septal defect closure
• Alcohol septal ablation for hypertrophic obstructive cardiomyopathy
• European Society of Medicine International Congress . Berlin , Germany . Invited Faculty . Lecture : TAVR in 2021 . August 2021 .
• Who Stole My 3rd Cusp ? Lifetime Management of Bicuspid Aortic Valve Disease . Cardiovascular Updates Symposium , Plano , Texas . February 2022 .
• Hot Topics in Structural Heart Disease : CRT Valve Aortic . Panelist . Cardiovascular Research Technologies - national meeting in Washington DC . February 2022 .
• TAVR Video Perspectives : Interview with Michael Mack , MD and Robert C . Stoler , MD . Healio . com . 2022 .
40
CENTER FOR VALVE DISORDERS
The full range of specialized Center for Valve Disorders interventions for patients with structural heart disease includes :
Aortic valve disease

• Minimally invasive surgical aortic valve repair / replacement

• TAVR for patients with severe aortic stenosis

• Transcatheter aortic valve-in-valve replacement for degenerated aortic valve bioprosthesis in patients with aortic stenosis or aortic insufficiency

Mitral valve disease

• Transcatheter mitral valve repair ( TMVR ) therapy for patients at high risk for surgical intervention

• Transcatheter mitral valve-in-valve replacement for degenerated mitral prosthesis in patients with mitral regurgitation or mitral stenosis

• Balloon mitral valvuloplasty for patients with mitral stenosis

Other specialized interventions

• Percutaneous tricuspid valve repair

• Left atrial appendage closure via percutaneous and minimally invasive approaches

• Percutaneous patent foramen ovale closure

• Percutaneous atrial septal defect closure

• Alcohol septal ablation for hypertrophic obstructive cardiomyopathy

Surgical aortic , mitral and tricuspid repair or replacement
Patients who are surgical candidates undergo full review by the multidisciplinary team through Center for Valve Disorders . Shared decision-making occurs between the Center for Valve Disorders team and patients regarding open surgical versus minimally invasive intervention .
VALVE-RELATED RESEARCH AND CLINICAL TRIALS
Key presentations Since the introduction of TAVR , Robert Stoler , MD , medical director of the hospital ’ s cardiac catheterization lab and co-director of the Division of Cardiology , has conducted transcatheter aortic and mitral valve studies leading to FDA approval of new technologies .
Dr . Stoler is also known for proctoring others and sharing best practice processes as well as speaking internationally on TAVR-related topics . In fiscal year 2022 , this included :

• European Society of Medicine International Congress . Berlin , Germany . Invited Faculty . Lecture : TAVR in 2021 . August 2021 .

• Who Stole My 3rd Cusp ? Lifetime Management of Bicuspid Aortic Valve Disease . Cardiovascular Updates Symposium , Plano , Texas . February 2022 .

• Hot Topics in Structural Heart Disease : CRT Valve Aortic . Panelist . Cardiovascular Research Technologies - national meeting in Washington DC . February 2022 .

• TAVR Video Perspectives : Interview with Michael Mack , MD and Robert C . Stoler , MD . Healio . com . 2022 .

Key clinical trials
The Center for Valve Disorders actively enrolls patients in clinical trials involving asymptomatic aortic stenosis , new generation valves , cerebral embolic protection , and functional and symptomatic mitral regurgitation through transcatheter mitral valve repair and replacement using new generation technology .
The Dallas campus was one of the highest volume sites using a nonsurgical option for high-risk patients who need medical attention for mitral valve regurgitation or another mitral valve disease but who are not candidates for mitral valve repair and replacement surgery . Interventional cardiologists on the medical staff were involved in the initial COAPT trial , which lead to the evolution of the device used to be clipped to the mitral valve . The latest generation is currently being used at Baylor Scott & White Heart and Vascular Hospital – Dallas . This is one example of the caliber of research related to aortic stenosis performed at the hospital .